Connor Clark & Lunn Investment Management Ltd. trimmed its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 6.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 201,569 shares of the specialty pharmaceutical company’s stock after selling 13,295 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned 0.37% of Supernus Pharmaceuticals worth $7,289,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds also recently modified their holdings of the company. Smartleaf Asset Management LLC grew its holdings in Supernus Pharmaceuticals by 219.1% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company’s stock valued at $47,000 after purchasing an additional 870 shares during the period. Newbridge Financial Services Group Inc. acquired a new position in shares of Supernus Pharmaceuticals in the 4th quarter valued at $72,000. Venturi Wealth Management LLC purchased a new stake in shares of Supernus Pharmaceuticals during the 4th quarter valued at $92,000. KBC Group NV increased its holdings in shares of Supernus Pharmaceuticals by 53.1% during the 4th quarter. KBC Group NV now owns 2,679 shares of the specialty pharmaceutical company’s stock worth $97,000 after buying an additional 929 shares during the last quarter. Finally, Janney Montgomery Scott LLC purchased a new position in shares of Supernus Pharmaceuticals in the 4th quarter worth $211,000.
Supernus Pharmaceuticals Trading Up 0.3 %
Shares of NASDAQ SUPN opened at $31.26 on Friday. The stock has a fifty day moving average price of $36.22 and a 200 day moving average price of $35.17. Supernus Pharmaceuticals, Inc. has a 12-month low of $25.53 and a 12-month high of $40.28. The company has a market cap of $1.74 billion, a P/E ratio of 29.22 and a beta of 0.83.
Insider Transactions at Supernus Pharmaceuticals
Wall Street Analysts Forecast Growth
SUPN has been the subject of several research analyst reports. StockNews.com upgraded Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Sunday. Cantor Fitzgerald reissued a “neutral” rating and set a $36.00 target price on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 26th.
Read Our Latest Stock Report on Supernus Pharmaceuticals
Supernus Pharmaceuticals Profile
Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.
Further Reading
- Five stocks we like better than Supernus Pharmaceuticals
- Conference Calls and Individual Investors
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- Growth Investing: Should You Adopt This Investing Strategy in 2022?
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report).
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.